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Abstract
In the article are presented the questions of classification, pathogenesis and clinical diagnostics of Hodgkin Lymphoma with 
soft-tissue paravetebral component. The difficulties of early diagnostics, expressed at the expanse by oncological process localiza-
tion, not typical for this disease, are shown on clinical case. 
The symptoms, conditioned by the compression of organs by tumor masses depend on pathological process localization: in-
trahepatic and extrahepatic obstruction of bile duct is manifested by jaundice; obstruction of lymphatic ducts in groin zone or in zone 
of small pelvic – by legs edema; at tracheobronchial compression is observed the pant and hoarse breathing; pulmonary abscesses 
or caverns can take place as a result of infiltration of pulmonary parenchyma that can stimulate lobar consolidation or bronchopneu-
monia; paraplegia can be observed because of epidural invasion with spine cord compression; compression of sympathetic cervical 
recurrent guttural nerve by increased lymph nodes can cause Horner’s syndrome and laryngoparalysis; neuralgias can be the result 
of nerve-root incarceration. 
Differential diagnostics can take a long time that lowers the effectiveness of therapy and decreases chances for recovery 
because of special treatment delay. The setting of correct diagnosis and choice of adequate therapy raises the chances for recovery, 
even at spead stage of tumor process that is attained at Hodgkin lymphoma in most cases. 
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1. Introduction
In most cases the diagnostics of Hodgkin Lymphoma is not difficult but in some cases is 
observed non-typical manifestation of disease, connected with localization of tumor masses near 
spine cord and nerve trunks with correspondent neurological symptomatology. 
2. Aim
To consider the difficulties of diagnostic search, features of clinical course of Hodgkin lym-
phoma with soft-tissue paravetebral component on the example of clinical case. 
3. Description of clinical case
The man, 27 years old was admitted to the department of oncohematology of National can-
cer institute (NCI) with complaints on pain between shoulder-blades, feeling of numbness in legs, 
expressed weakness, convulsions, impossibility to move independently. The anamnesis of disease: 
felt ill since the beginning of 2015, when started to observe the numbness, weakness in right leg, 
disturbance of perceptibility in legs. He addressed to neurologist domiciliary. He underwent mag-
netic-resonance tomography of thoracic spine: MR picture of extra- and intradural volume mass at 
the level of Th1-Th5 vertebra on the left, Th10-Th12 vertebra on the right and Th12-L1 vertebra on 
the left; stenosis of vertebral canal at the level of Th1-Th4 with the signs of myelopathy. The signs 
of injury were in the body of Th9, Th12 vertebra. The biopsy of mass was carried out at neurolog-




ical department of Kiev hospital: hemilaminectomy of Th1-Th4 on the left, partial elimination of 
tumor (intravertebral component was totally eliminated) at the level of Th1-Th4 vertebra. Decom-
pression of spine cord. Histologic conclusion: PHC № 7067-7113/15 – schwannoma.
Schwannoma (neurinoma, schwannoglioma, lemmoblastoma, perineural fibroplasto-
ma) – tumor, growing from Schwann cells that form myelin nerve coat. The term was offered by 
Verokai and widely spread. 
Schwannomas are benign tumors, are observed in any age, more often in women. Most of-
ten localization is auditory nerve. They can occur on any nerves of human organism [1].
Macroscopically schwannoma looks as a dense, limited node of oval or odd shape. The node 
surface is uneven, bumpy. Schwannoma is covered with connective capsule. The tissue of tumor 
on the cut is faintly grey, with part of yellow, rusty tint at the expanse of fatty deposition or brown 
color (the evidence of old hemorrhages). The color of tissue can change depending on conditions of 
tumor blood supply: at venous congestion it acquires cyanotic tint. In tumor tissue often occur cysts 
of different sizes, filled with brown liquid. Cystic degeneration can be detected in whole tumor or 
its part. The spread fields of fibrosis are often observed. 
The diverse transformations, appeared as the result of dystrophic processes, inherent to 
schwannomas, caused the separation of different histologic types: epithelioid – with dense place-
ment of cells and weak expressiveness of fibrous tissue; angimatous – with mass of cavernous 
cavities; xanthomatous – with significant crowd of xanthome cells. 
Schwannomas (neurinomas) usually don’t infiltrate the surrounding tissues but cause their 
intensive compression [2]. Malignization is rather seldom. It is attended with change of morpholog-
ical presentation that acquires similarity with so-called neurogenic sarcomas. Clinical presentation 
depends on schwannoma localization. The symptoms of irritation and compression of spine cord 
develop at schwannomas of roots of spine cord. At schwannomas of peripheral nerves the clinical 
presentation consists of symptoms of irritation and prolapsed of functions of correspondent nerves. 
At typical forms of neurinomas the clinical course is slow, benign. Magnetic-resonance tomog-
raphy is a method of choice at diagnostics. The treatment of disease is mainly surgical; the radial 
therapy is used at large sizes of tumor or when surgical intervention is technically impossible. The 
prognosis of disease is mainly favorable; after adequate treatment disease is completely eliminated 
without consequences for patient. 
After pathohistologic diagnosis as schwannoma patient was sent for further treatment and 
examination to the department of oncohematology of CNI (Cancer national institute). Objectively: 
general status is relatively satisfactory (ЕCOG 1). Neurological status: is conscious, oriented in 
space, palpebral fissure D=S, pupils D=S, photoreaction is a little lowered. Tendon reflexes are 
high, on the right higher than at the left, knee and Achilles – with polykinetic response. The deep 
low pyramidal paraparesis of low extremities, decrease of muscular force in legs is 0–1 point, 
hypesthesia at the level Th5-Th6, stagger in Romberg position, finger-nasal test is executed with 
miss-hit from the right. Babinsky symptom is negative from two sides, meningeal signs are absent. 
The general blood analysis – insignificant leucocytosis, ESR acceleration, in biochemical 
blood analysis were observed hypoproteinuria, insignificant increase of AcT and AlT. In myelogram 
from iliac bone: blast cells – 2,25; lymphocytes – 4,25; promyelocytes – 0,25; myelocytes – 17,25; 
y. – 5,25; st/k – 10,25; sig/k – 17,7 erythrocyte appendage – 40,75; plasmatic cells – 2. The function 
of megacaryocytic appendage is preserved. In biopsy material from iliac bone is the normal pre-
sentation of marrow. 
According to CT data of neck, breast organs, small pelvis organs: thrombosis of inter-
nal jugular vein. Conglomerate of increased lymph nodes is at the level of aorta bifurcation (l/n) 
45×39 mm, paraaortic l/n 23×22 mm. Iliac l/n on the right 29×31 mm, on the left 18×53 mm. Ob-
turative l/n on the right 23×55 mm, on the left 27×57 mm. Groin l/n on the right 32×27 mm, on the 
left 30×29 mm. 
In pathohistologic CNI department the biopsy material was revised: pathohistologic conclu-
sion № 7067-7113/15, immune-histochemical study № 2307/15: CD20-; CD3+; CD4 +; CD8-; Ki-67 
to 22 %; Granzyme B-, CD 30-. Conclusion: peripheral T-cellular lymphoma (NOS). 




Unclassified peripheral T-cellular lymphoma – tumors, generated from mature (post-thy-
mic) T-lymphocytes and NK-cells. This rare group of diseases is characterized with pathobiological 
heterogenity and is near 15 % of all lymphomas. This category is the diagnosis of exclusion that in-
cludes all Т-cellular lymphomas, not related to other subvariants, according to WHO classification. 
The timorous cells are characterized with clonal rebuilding of T-cellular receptor, often CD3 and 
СD30-positive. Specific genetic and immune- phenotypic features are absent [3].
In connection with disagreement of diagnoses, according to the conclusions of CNI and 
Kiev hospital, conference made a decision about revision of biopsy material in one more laboratory. 
The second histologic and immune-histochemical study was carried out: CD20+; CD3-; CD15+; 
CD30+; CD5-; ОСТ2 weakly+; ВОВ 1-; Ki-67 + mainly in most timorous cells. Conclusion: his-
tologic creation of tumor cells and immune phenotype correspond to classic Hodgkin lymphoma, 
mixed-cellular variant. 
In connection with received three different results it was recommended to revise prepara-
tion in one more laboratory. According to the results of repeated studies, the tumor cells expressed 
CD20+; CD3-; CD15+; CD30+; CD45-. Conclusion: histologic structure of tumor cells and im-
mune phenotype correspond to classic Hodgkin lymphoma, variant of nodular sclerosis. 
Hodgkin lymphoma (HL) – malignant disease of lymphoid tissue, which morphological 
substrate is a presence of huge cells of Reed-Beresovsky-Stenberg at microscopic study of in-
jured lymphatic nodes. This variant of lymphoma is 11 % of all lymphomas. Morbidity is 2,9 for 
100 000 people. Men have it more often than women (1,4:1). Hodgkin lymphoma can appear at 
any age, but there are two peaks of morbidity: 20–29 years old and at the age older than 55 year. 
As opposite to other lymphatic malignant mass, Hodgkin lymphoma is not associated with typical 
genetic injuries [4]. 
There are two main forms of this disease: classic Hodgkin lymphoma that is 95 % of all 
cases and nodular type of lymphoid prevalence of Hodgkin disease (Hodgkin lymphoma with lym-
phoid prevalence, HLLP) – 5 % of cases. These forms differ by histologic presentation and clinical 
course (Table 1). Nodular Hodgkin lymphoma with lymphoid prevalence is characterized with 
more favorable prognosis. This form is more often occurs in men 30–50 years old. 
Table 1
Determination of HL risk groups in correspondence with EORTC/LYSA and GHSG classifications
Stages Classification according to EORTC/LYSA Classification according to GHSG
Early stages CS I-II (epiphrenic injury) without risk factors CS I-II Without risk factors 
Intermediate stages CS I-II (epiphernic injury) ≥ 1 risk factor CS I, IIA ≥1 risk factor;  КС IIB with risk factors C/D, without A/B
Spread stages CS III-IV CS IIB with risk factors А/В, CS III/IV
Risk factors
(А) big mass in mediastinum 
(В) age ≥50 years old
(С) increased ESR
(D) ≥4 lymph node zones
(А) big mass in mediastinum  
(В) presence of extranodal injury  
(С) increased ESR 
(D) ≥3 lymph node zones
Note: CS – clinic stage, EORTC – European Organisation for Research and Treatment of Cancer, ESR – erythrocyte sediment rate, 
GHSG – German Hodgkin Study Group, LYSA – Lymphoma Study Association
The classic Hodgkin lymphoma is divided in four subtypes by histologic signs: nodular 
sclerosis or sclerosing lymphoma (70 % of cases): most spread in USA, more often in women and 
young patients. Mixed-cellular (20 % of cases): most spread among patients with HIV. Rich in lym-
phocytes (3–5 % of cases). Lymphoid exhaustion (2 % of cases). Lymphoid exhaustion was only 
recently more spread subtype but since diagnostic methods in oncology were improved, the number 
of cases of this variant of disease decreased. 
The symptoms, conditioned by compression of organs by timorous masses depend on patho-
logic process localization: intra-hepatic and extra-hepatic obstruction of bile duct is manifested by 
jaundice; obstruction of lymphatic ducts in groin zone or in zone of small pelvic – by legs edema; at 




tracheobronchial compression is observed the pant and hoarse breathing; pulmonary abscesses or 
caverns can take place as a result of infiltration of pulmonary parenchyma that can stimulate lobar 
consolidation or bronchopneumonia; paraplegia can be observed because of epidural invasion with 
spine cord compression; compression of sympathetic cervical recurrent guttural nerve by increased 
lymph nodes can cause Horner’s syndrome and laryngoparalysis; neuralgias can be the result of 
nerve-root incarceration. 
The diagnosis Hodgkin Lymphoma (HL) is set according to the criteria of World Health Or-
ganization (WHO) on the base of the study of operational material, excisional or incisional biopsy 
of lymphatic node under condition of sufficient quantity of diagnostic material. For histologic pre-
sentation of classis HL is typical the reactive microenvironment and big timorous cells of Hodgkin 
or Reed-Sternberg (HRS-cells), whereas for the variant of nodular HL with lymphoid prevalence 
is necessary to find LP-cells (big cells with multiblade kernels, reminding of popcorn) [4, 5]. HRS-
cells are positive at coloration with antibodies to CD30 and CD15, sometimes CD20-positive (part 
of timorous cells) and negative at antibodies use to CD45. LP-cells are characterized with mono-
morphic expression of CD20 and CD45, but don’t express CD15 and CD30 [6].
The full recovery after use of standard polychemotherapy (PCT) courses can be attained in 
more than 80 % of patients (ESMO book).
For the choice of therapy practice it is necessary to determine the risk group of patient 
before the beginning of treatment. The risk group of patient depends on number of factors of 
unfavorable prognosis. These factors include: ESR increase >50 mm/hour at absence of В-symp-
toms and >30 mm/hours at В-symptoms; big mass in mediastinum (mass with size as more than 
one third of maximal horizontal diameter of chest), В-symptoms (increase of body temperature, 
night sweats, unexplained loss of body weight >10 % during 6 months), presence of extranodal 
injury and more than 3 involved l/n zones. 
The treatment of HL spread stages. 
The standard of treatment at spread stages is chemotherapy. The radial therapy (RT) is used 
in some patients after chemotherapy [7].
Patients at ≤60 years old can receive from six to eight cycles according to ABVD scheme, 
with further local RT on residual nidi of timorous injury with size more than 1,5 cm or six cycles of 
BEACOPP escalated, with further local RT on PET-positive residual timorous nidi with size more 
than 2,5 cm.
The treatment results according to BEACOPP escalated scheme are possibly better com-
paring with ones according to ABVD. The treatment according to BEACOPP escalated scheme is 
attended with more toxicity and needs the associated therapy [8, 9].
BEACOPP escalated must not be used in patients >60 years because of high mortality, con-
nected with treatment [10].
ABVD is a standard of treatment for elder patients that multicomponent chemotherapy can 
be applied in. According to the data of several studies [14, 15], intermediate (PET/CT study after 
1–2 courses of PCT has a great prognostic importance. 
After repeated revision of all consulting conclusions of 3 pathohistologic laboratories 
and biopsy material there was set diagnosis as Hodgkin lymphoma of ІV А stage with injury 
of Th1-Th5 vertebra on the left, Th10-Th12 vertebra on the right and Th12-L1 vertebra on the left, 
conglomerate of increased lymphatic nodes, paaraortic lymphatic nodes, ilioinguinal lymphatic 
nodes, obtrutive lymphatic nodes at the level of aorta bifurcation. The status after hemilaminecto-
my operation (09.11.15) of Th1-Th4 on the left, partial elimination of tumor (intravertebral compo-
nent is totally eliminated) at the level of Th1-Th4 vertebra. Decompression of spine cord. Throm-
bosis of internal jugular vein. 
In connection with aggressive debut of disease and spreading of process, patient underwent the 
specific therapy according to intensive chemotherapy scheme BEACOPP-esc (6 courses). Rated doses: 
Cyclophosphamide 1250 mg/m2 – 2600 mg, Doxorubicine 35 mg/m2 – 70 mg, Etoposide 200 mg/m2 – 
400 mg (1–3 days, totally 1200 mg), Bleomycin 10 mg/m2 – 21 mg , Vincristine 1.4 mg/g2 – 2 mg, Pred-
nisolone 40 mg/m2 – 80 mg (1–14 days totally 1120 mg), procarbazine – 100 mg/m2 200 mg (1–7 days 




totally 1400 mg). Associated therapy: ondansetron 8 mg № 5, heptral 400 mg № 14, uromitexan – 400 
mg № 6, allopurinol 600 mg/day, mg/day, lansoprazole 30 mg/day. 
The complications developed after therapy: leucopenia of 4 degree to 0,02 g/l. In connection 
with it patient received clonal-stimulating factors, antibacterial therapy, antifungal therapy. For 
assessment of intermediate response patient underwent PET-CT, after 4 courses of BEACOPP-esc. 
According to PET-CT data, in spine soft tissues at Th1-Th5 level was visualized RPP with intensity 
SUV=6.1. The signs of residual mass are Deauville criteria score 3. (PET-negative) that testifies to 
the absence of timorous activity. 
4. Results
After the end of study PET-CT was also carried out. According to the data of PET-CT, the 
absence of biologically active masses was observed. The assessment of response was carried out 
according to Deauville criteria. The full metabolic response to the treatment was attained. 
5. Conclusions
The full recovery at Hodgkin lymphoma is possible in 80–90 % of patients [4], including at 
injury of spine cord. 
It is very seldom, when clinical presentation of Hodgkin lymphoma conditions the signifi-
cant complications in early diagnostics that is principally important for timely beginning of specific 
therapy. 
The injury of lymphatic nodes in combination with extramedular intradural volume neo-
plasm usually occurs at non-Hodgkin lymphomas of extranodal type or peripheral T-cellular lym-
phomas, NOS, and is no typical for HL that complicates and delays the terms of diagnosis setting as 
it was presented in considered clinical case. The term from the moment of first histologic diagnosis 
to the setting of final one and beginning of the therapy was 6 months. 
Neurological symptomatology and localization of process could correspond to the schwan-
noma diagnosis, but because of spreading of process, biopsy material was sent to another labo-
ratory for revision. The disagreement of diagnoses in different laboratories always indicates the 
complicated diagnostic case. In this situation it is expedient to address to conference and set the 
correct diagnosis together. 
The setting of correct diagnosis before the beginning of therapy is a guarantee of treatment 
effectiveness as it was demonstrated on the example of patient. Despite the severe status and large 
spreading of process, the adequately prescribed treatment allowed attaining the full response to 
therapy. 
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